We are live on
!
Find out more
Two Sigma Investments Portfolio holdings
AUM
$124B
1-Year Est. Return
33.93%
This Fund
S&P 500
This Quarter
Est. Return
+9.67%
1 Year Est. Return
+33.93%
3 Year Est. Return
+96.56%
5 Year Est. Return
+105.93%
10 Year Est. Return
+538.88%
AUM
$42.6B
AUM Growth
-$927M
(-2.1%)
Cap. Flow
-$4.42B
Cap. Flow
% of AUM
-10.38%
Top 10 Holdings %
Top 10 Hldgs %
9.02%
Holding
3,518
New
408
Increased
1,022
Reduced
1,392
Closed
532
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$244M |
| 2 |
Pfizer
PFE
|
+$234M |
| 3 |
Nike
NKE
|
+$201M |
| 4 |
Tesla
TSLA
|
+$200M |
| 5 |
S&P Global
SPGI
|
+$196M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$305M |
| 2 |
Advanced Micro Devices
AMD
|
+$241M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$231M |
| 4 |
Merck
MRK
|
+$199M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.1% |
| 2 | Healthcare | 11.63% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.76% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2651
Metagenomi Therapeutics
MGX
$46.3M
| $213K | ﹤0.01% |
+20,159
| New | +$232K |
|
2652
Xperi
XPER
$348M
| $212K | ﹤0.01% |
17,600
-90,661
| -84% | -$997K |
|
2653
BlackRock Science and Technology Term Trust
BSTZ
$2.07B
| $212K | ﹤0.01% |
+10,935
| New | +$196K |
|
2654
NN Inc
NNBR
$311M
| $212K | ﹤0.01% |
44,654
-36,064
| -45% | -$166K |
|
2655
Stoneridge
SRI
$213M
| $210K | ﹤0.01% |
11,409
-3,027
| -21% | -$53.7K |
|
2656
PennyMac Financial
PFSI
$4.02B
| $210K | ﹤0.01% |
2,300
-19,100
| -89% | -$1.67M |
|
2657
Asure Software
ASUR
$250M
| $209K | ﹤0.01% |
26,912
-29,543
| -52% | -$265K |
|
2658
Stoke Therapeutics
STOK
$2.11B
| $209K | ﹤0.01% |
15,500
+4,300
| +38% | +$26.1K |
|
2659
ARS Pharmaceuticals
SPRY
$612M
| $209K | ﹤0.01% |
20,417
-41,308
| -67% | -$308K |
|
2660
PUT
Bain Capital Specialty
BCSF
$850M
| $209K | ﹤0.01% |
13,300
| – | – |
|
2661
Autoliv
ALV
$9B
| $208K | ﹤0.01% |
1,730
-17,656
| -91% | -$1.98M |
|
2662
Teleflex
TFX
$5.98B
| $208K | ﹤0.01% |
+920
| New | +$219K |
|
|
PDCO
2663
DELISTED
Patterson Companies, Inc.
PDCO
| $207K | ﹤0.01% |
7,484
-7,069
| -49% | -$201K |
|
2664
AudioCodes
AUDC
$253M
| $207K | ﹤0.01% |
15,850
-20,636
| -57% | -$263K |
|
2665
iShares Core S&P Mid-Cap ETF
IJH
$127B
| $207K | ﹤0.01% |
+3,400
| New | +$192K |
|
2666
Fulgent Genetics
FLGT
$527M
| $206K | ﹤0.01% |
+9,500
| New | +$236K |
|
|
AFCG
2667
AFC Gamma
AFCG
$63.4M
| $206K | ﹤0.01% |
24,298
-65,102
| -73% | -$529K |
|
2668
Voyager Therapeutics
VYGR
$201M
| $206K | ﹤0.01% |
22,112
+12
| +0.1% | +$101 |
|
2669
Ardagh Metal Packaging
AMBP
$3.01B
| $206K | ﹤0.01% |
+59,952
| New | +$215K |
|
2670
XPEL
XPEL
$1.38B
| $205K | ﹤0.01% |
+3,800
| New | +$199K |
|
2671
Smith & Wesson
SWBI
$637M
| $205K | ﹤0.01% |
+11,811
| New | +$170K |
|
2672
Marcus & Millichap
MMI
$1.19B
| $205K | ﹤0.01% |
+6,000
| New | +$220K |
|
|
FIRY
2673
Firy Inc
FIRY
$163M
| $205K | ﹤0.01% |
31,571
-21,369
| -40% | -$131K |
|
2674
Immunovant
IMVT
$8.25B
| $205K | ﹤0.01% |
6,331
-72,768
| -92% | -$2.65M |
|
2675
Mineralys Therapeutics
MLYS
$2.41B
| $202K | ﹤0.01% |
15,624
-49,099
| -76% | -$606K |
|
Similar funds
VAM
Two Sigma Investments's Q1 2024 Portfolio in Review
As of Q1 2024, Two Sigma Investments held 3,518 positions worth $42.6B, down 2.1% from $43.5B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Two Sigma Investments withdrew a net $4.42B in Q1 2024, closing 532 positions and reducing 1,392 holdings. Its most notable exit was Rivian, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Two Sigma Investments opened a new position in Pfizer worth $234M.
- Two Sigma Investments's largest Q1 2024 buy was Pfizer: 8,419,014 shares worth $234M.
- Two Sigma Investments added most to Gilead Sciences in Q1 2024, an estimated $244M increase.
- Two Sigma Investments's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $305M.
- Two Sigma Investments fully exited Rivian in Q1 2024, selling an estimated $158M.
- Two Sigma Investments's ten largest holdings make up 9% of its $42.6B portfolio in Q1 2024.
- Two Sigma Investments opened 408 new positions and closed 532 in Q1 2024.
- Two Sigma Investments's portfolio value fell 2.1% quarter-over-quarter to $42.6B.
Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.